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138letter to editorBortezomib
plus dexamethasone
results in a late organ
response in primary
heavy-chain amyloidosis
without a hematologic
responseTo the Editor: Amyloidosis
encompasses a group of diseases
deﬁned by the abnormal deposi-
tion of insoluble ﬁbrillary proteins
in various organs. Heavy-chain
amyloidosis is rarely observed in
clinical practice and is character-
ized by the deposition of the
immunoglobulin heavy chain in
the affected organs. As in light-
chain amyloidosis, therapy is
aimed at decreasing the production
of the amyloidogenic protein by
the plasma cell clone (hematologic
response), which is a prerequisite
for organ response.1,2
We report a patient with pri-
mary heavy-chain renal amyloido-
sis (AH) who, when treated with
bortezomib and dexamethasone,
had an organ response without
achieving a hematologic response.
The patient is a 57-year-old
man who presented to our clinic
with symptomatic anemia, as well
as progressive renal failure associ-
ated with proteinuria over a ﬁve-
year period. During that time, a
work-up noted evidence of aFigure 1. Changes in disease parameters from
variables in the same graph.monoclonal gammopathy with an
IgG kappa M-spike measuring
0.7 g/dL. Skeletal survey was nota-
ble for the absence of lytic lesions,
and a bone marrow biopsy showed
less than 1% plasma cells. His ini-
tial 24-hour urine protein and
electrophoresis analyses showed a
total protein of 1.19 g/24 h (IgG
kappa = 47 mg/24 h). His pro-
teinuria worsened; two years later
it reached 11,627 mg/24 h (IgG
kappa = 1,039 mg/24 h). A renal
biopsy was consistent with amyloi-
dosis with focal global glomeru-
losclerosis, sparing arteries and
arterioles. However, immuno-
ﬂuorescence was negative for
kappa or lambda light chain. Mass
spectrometry was then performed
and showed presence of IgH,
serum amyloid P, and apolipopro-
tein E, which conﬁrmed a diagno-
sis of heavy-chain amyloid. At
that time, the serum M-spike and
patient’s serum kappa/lambda
free-light chain ratio were 0.5 g/dL
and 1.45, respectively. A repeat
bone marrow aspirate and biopsy
showed 2% plasma cells with nor-
mal karyotype by conventional
chromosome banding as well as
ﬂuorescence in situ hybridization.
The patient had no clinical
evidence of cardiac involvement.
The patient received eight cycles
of intravenous bortezomibtime of presentation. Various units are used to
Hema(1.3 mg/m2 on days 1, 4, 8, and
11) and a weekly dose of 20 mg
of dexamethasone on a 21-day
cycle. He was maintained on dex-
amethasone during follow-up.
After eight cycles of therapy, his
24-hour urine was notable for a
persistently high level of protein-
uria at 12,188 mg/24 h (IgG kap-
pa = 815 mg/24 h) and M-spike
of 0.3 g/dL. Interestingly, 10
months after initiation of therapy,
the patient achieved a measurable
renal response with a drop in
the urine protein level from
11.6 g/24 h at initiation of therapy
to 2.1 g/24 h. Nevertheless, a
hematologic response was absent
(Figure 1).
This case demonstrates that
bortezomib plus dexamethasone
followed by dexamethasone main-
tenance can produce a renal
response in a patient with AH
amyloidosis, but without hemato-
logic response. Interestingly,
improvement in proteinuria
occurred 10 months after ini-
tiation of therapy, hence raising
caution on labeling such cases as
treatment failures too prematurely,
especially when stable disease is
the best observable response
achieved during the earlier phases
of therapy. Treatment recommen-
dations for AH amyloidosis have
been generally extrapolated frombetter illustrate change over time in multiple
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clinical experiences with AL amy-
loidosis. Clinical experience with
AL amyloidosis shows that a
hematological response is in most
cases a prerequisite for an organ
response. Moreover, a better
hematologic response seems to
translate into improved organ
response.3,4 Based on limited lit-
erature pertaining to treatment of
AH amyloidosis, one might antici-
pate analogous outcomes to those
seen in AL amyloidosis. Our case,
however, is unique in the sense
that an organ response was
documented in the absence of a
hematologic response. The reasons
for the unique response behavior
observed in our case are not entire-
ly clear. One might postulate that
therapy may have been successful
at ‘‘eradicating’’ a subclone of cells
expressing the predominant amy-
loidogenic heavy chain while the
overall serum M-spike was not
markedly changed.SUPPORT
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